{"id":43993,"date":"2025-10-21T20:43:12","date_gmt":"2025-10-21T12:43:12","guid":{"rendered":"https:\/\/flcube.com\/?p=43993"},"modified":"2025-10-21T20:43:13","modified_gmt":"2025-10-21T12:43:13","slug":"summit-therapeutics-plans-u-s-fda-bla-submission-for-ivonescimab-chemotherapy-in-egfr%e2%80%91mutated-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43993","title":{"rendered":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Summit Therapeutics, the former China partner of Akeso Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>), announced today that it will file a <strong>Biologics License Application (BLA)<\/strong> with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for <strong>ivonescimab (AK112)<\/strong> in combination with standard chemotherapy for patients with <strong>EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC)<\/strong> that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ivonescimab (AK112)<\/strong> \u2013 a first\u2011in\u2011class PD\u20111\/VEGF bispecific antibody that merges <strong>immuno\u2011oncology<\/strong> with <strong>anti\u2011angiogenesis<\/strong>.<\/li>\n\n\n\n<li><strong>Established Clinical Success<\/strong> \u2013 Approved by China\u2019s National Medical Products Administration (NMPA) in May\u202f2024 for locally advanced or metastatic non\u2011squamous NSCLC post\u2011EGFR\u2011TKI.<\/li>\n\n\n\n<li><strong>Market Impact<\/strong> \u2013 Became the world\u2019s first bispecific antibody approved for oncology, and was added to China\u2019s National Reimbursement Drug List (NRDL) in November\u202f2024.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-milestone\">Strategic Milestone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. Expansion<\/strong> \u2013 Summit\u2019s Q4\u202f2025 BLA submission will extend ivonescimab\u2019s reach to the largest oncology market, targeting a subset of NSCLC patients with limited options after TKI failure.<\/li>\n\n\n\n<li><strong>Combination Therapy<\/strong> \u2013 The proposed regimen pairs ivonescimab with chemotherapy, leveraging synergistic mechanisms to enhance tumor control.<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> \u2013 Summit\u2019s prior U.S. licensing of ex\u2011China rights (December\u202f2022) positions it to navigate FDA review efficiently.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-context\">Company Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Summit Therapeutics<\/strong> \u2013 Focused on bringing innovative oncology therapies to the U.S., leveraging strategic partnerships.<\/li>\n\n\n\n<li><strong>Akeso Inc.<\/strong> \u2013 Continues to develop and commercialize ivonescimab worldwide, with Summit handling U.S. launch and commercialization.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43994,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[360,16,850,38,28,712],"class_list":["post-43993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-cancer","tag-hkg-9926","tag-market-approval-filings","tag-multi-specific-antibodies","tag-summit-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43993\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC\" \/>\n<meta property=\"og:description\" content=\"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43993\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T12:43:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T12:43:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC\",\"datePublished\":\"2025-10-21T12:43:12+00:00\",\"dateModified\":\"2025-10-21T12:43:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2102.webp\",\"keywords\":[\"Akeso Biopharma\",\"Cancer\",\"HKG: 9926\",\"Market approval filings\",\"Multi-specific antibodies\",\"Summit Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43993#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43993\",\"name\":\"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2102.webp\",\"datePublished\":\"2025-10-21T12:43:12+00:00\",\"dateModified\":\"2025-10-21T12:43:13+00:00\",\"description\":\"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43993\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43993#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43993","og_locale":"en_US","og_type":"article","og_title":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC","og_description":"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.","og_url":"https:\/\/flcube.com\/?p=43993","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-21T12:43:12+00:00","article_modified_time":"2025-10-21T12:43:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43993#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43993"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC","datePublished":"2025-10-21T12:43:12+00:00","dateModified":"2025-10-21T12:43:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43993"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43993#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","keywords":["Akeso Biopharma","Cancer","HKG: 9926","Market approval filings","Multi-specific antibodies","Summit Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43993#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43993","url":"https:\/\/flcube.com\/?p=43993","name":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43993#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43993#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","datePublished":"2025-10-21T12:43:12+00:00","dateModified":"2025-10-21T12:43:13+00:00","description":"Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it will file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in Q4\u202f2025. The application seeks approval for ivonescimab (AK112) in combination with standard chemotherapy for patients with EGFR\u2011mutated, non\u2011squamous non\u2011small\u2011cell lung cancer (NSCLC) that has progressed after third\u2011generation EGFR\u2011tyrosine kinase inhibitor (TKI) therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43993#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43993"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43993#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","width":1080,"height":608,"caption":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43993#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR\u2011Mutated NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43993"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43993\/revisions"}],"predecessor-version":[{"id":43995,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43993\/revisions\/43995"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43994"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}